click below
click below
Normal Size Small Size show me how
Antibiotics/ B
Antibiotics, dosage
Name of the AB | Group of antibiotic | Coverage | Adult dose | Children dose |
---|---|---|---|---|
Oxacillin | Penicillinase (β-lactamase) Resistant PCNs | Exclusively effective against Gram+ cocci, in particular staphylococci | 1-2 g q4h iv | 50-100 mg/kg/d q4-6h iv |
Nafcillin | Penicillinase (β-lactamase) Resistant PCNs | Exclusively effective against Gram+ cocci, in particular staphylococci | 1-2 g q4h iv | 50-100 mg/kg/d q4-6h iv |
Dicloxacillin | Penicillinase (β-lactamase) Resistant PCNs | Exclusively effective against Gram+ cocci, in particular staphylococci | 125–500 mg q6h po | 12.5-25 mg/kg/d q6h po |
PCN G | PCNs | Effective against strep | 1–4 mU q4–6h iv | 25,000-400-000 U/kg/d q4-6h iv |
PCN V | PCNs | Effective against strep | 250–500 mg q6–12h po | 20-40 mg/kg/d q8h po |
Amoxi | PCNs | Effective against strep; Effective against staph if with clavulanate; also active against neisseria, enterococci, and listeria | 250-500 mg q8h po | 40 mg/kg/d bid/tid po |
Amoxi/clav | PCNs | Effective against strep, staph | ER: 2 g bid po | ES-600: 90 mg/kg/d bid po |
Ampi | PCNs | Effective against strep; Effective against staph if with sulbactam; also active against neisseria, enterococci, listeria and somehow E-coli | 0.5–2.0 g q4–6h iv | 100–200 mg/kg/d q6h iv |
Ampi/sulbactam | PCNs | Effective against strep, staph | 1.5–3.0 g q6h iv | 100–200 mg/kg/d q6h iv |
Cephalexin | First generation cephalosporines | Coverage like PCNase resistant Abs + Moraxella and E-Coli | 250–500 mg q6h po | 25–50 mg/kg/d tid / qid po |
Cefadroxil | First generation cephalosporines | Coverage like PCNase resistant Abs + Moraxella and E-Coli | 0.5–1 g q12h po | 30 mg/kg/d bid po |
Cefazolin | First generation cephalosporines | Coverage like PCNase resistant Abs + Moraxella and E-Coli | 1–2 g q8h iv | 50–150 mg/kg/d tid iv |
Cefprozil | Second generation cephalosporines | Coverage like 1st generation + more G- : such as providencia, haemophilus, klebsiella, citrobacter, morganella, and proteus | 250-500 mg q12-24h po | 30 mg/kg/d bid po |
Cefuroxime | Second generation cephalosporines | Coverage like 1st generation + more G- : such as providencia, haemophilus, klebsiella, citrobacter, morganella, and proteus | 125–500 mg q12h po /// 0.75–1.5 g q6–8h iv | 20–30 mg/kg/d bid po /// 75–150 mg/kg/d q8h iv |
Cefoxitin | Second generation cephalosporines | Coverage like 1st generation + more G- : such as providencia, haemophilus, klebsiella, citrobacter, morganella, and proteus | 1-2 g q4-8h iv | 75–150 mg/kg/d q6-8h iv |
Erythromycin | Macrolids | Alternatives to PCNs and cephalosporins for Gram+ infections (when allergic), also H. Pylori, Toxo, Mycoplasma; not good for serious staph infections | 250-500 mg q6h po | 40 mg/kg/d q6-8h po |
Azithromycin | Macrolids | Alternatives to PCNs and cephalosporins for Gram+ infections (when allergic), also H. Pylori, Toxo, Mycoplasma; not good for serious staph infections | 500 mg on day 1, then 250 mg od X4d po /// 500 mg od iv | 10 mg/kg/day on day 1, then 5 od X4d po /// iv N/A |
Clarithromycin | Macrolids | Alternatives to PCNs and cephalosporins for Gram+ infections (when allergic), also H. Pylori, Toxo, Mycoplasma; not good for serious staph infections | 250–500 mg q12h po | 15 mg/kg/d bid po |
Levofloxacin | fluoroquinolones, Respiratory | Alternatives to PCNs and cephalosporins for Gram+ infections. Excellent for strep, in particular S pneumonia | 250–750 mg od iv or po | N/A |
Moxifloxacin | fluoroquinolones, Respiratory | Alternatives to PCNs and cephalosporins for Gram+ infections. Excellent for strep, in particular S pneumonia | 400 mg od iv or po | N/A |
Clindamycin | Lincosamides | Alternatives to PCNs and cephalosporins for Gram+ infections. Excellent for strep, in particular S pneumonia | 150–450 mg q6h po /// 600-900 mg q6-8h iv | 8–20 mg/kg/d q6-8h po /// 20–40 mg/kg/d q6-8h iv |
Vancomycin | Vancomycin | Alternatives to PCNs and cephalosporins for Gram+ infections (when allergic) and serious staph infection; also for C. difficile enteropathy | 125-500 mg q6h po /// 500 mg q6h iv | 40 mg/kg/d q6-8h po and iv |
Linezolid & | Others | Alternatives to PCNs and cephalosporins for Gram+ infections (when allergic) and serious staph infection; the only oral medication agains MRSA | 600 mg q12h iv | 30 mg/kg/d q8h iv |
Piperacillin | PCNs with G- bacilli and rods coverage | Active against the full range of Gram- bacilli, such as the Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as Pseudomonas | 3 g q4-6h iv | 200 mg/kg/d q4-6h iv |
Piperacillin/tazo | PCNs with G- bacilli and rods coverage | Active against the full range of Gram- bacilli, such as the Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as Pseudomonas; Also Staph | 3.375 g q4-6h iv | 240 mg/kg/d q8h iv |
Ticarcillin | PCNs with G- bacilli and rods coverage | Active against the full range of Gram- bacilli, such as the Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as Pseudomonas | 3 g q4-6h iv | 200 mg/kg/d q4-6h iv |
Ticarcillin/clav | PCNs with G- bacilli and rods coverage | Active against the full range of Gram- bacilli, such as the Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as Pseudomonas; Also Staph | 3.1 g q4-6h iv | 200 mg/kg/d q4-6h iv |
Ceftazidime | Third Generation cephalosporines | All G- organisms; also pseudomonas | 1-2 g q8-12h iv | 75–150 mg/kg/d q8h iv |
cefotaxime | Third Generation cephalosporines | All G- organisms | 1-2 g q4-12h iv | 75-250 mg/kg/d q4-6h iv |
ceftriaxone | Third Generation cephalosporines | All G- organisms | 1-2 g od iv | 50 mg/kg/d od/bid iv |
cefepime | Fourth Generation cephalosporines | All G- organisms; also pseudomonas | 1-2 g q8-12h iv | 100-150 mg/kg/d q8-12h iv |
Ciprofloxacin | fluoroquinolones | Cover Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) and pseudomonas as well as:Mycoplasma, Chlamydia, and Legionella | 500-750 mg q12h po /// 200-400 mg q8-12h iv | 20-30 mg/kg/d q12h po or iv |
Levofloxacin & | fluoroquinolones | Cover Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as:Mycoplasma, Chlamydia, and Legionella | 250–750 mg od iv or po | N/A |
Moxifloxacin & | fluoroquinolones | Cover Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as:Mycoplasma, Chlamydia, and Legionella | 400 mg od iv or po | N/A |
Ofloxacin | fluoroquinolones | Cover Enterobacteriaceae (E. coli, Proteus, enterobacter, citrobacter, morganella, serratia, and klebsiella) as well as:Mycoplasma, Chlamydia, and Legionella | 200–400 mg q12h po /// 400 mg q12h iv | N/A |
Gentamicin | Aminoglycosides | G- organisms | 5-7 mg/kg qd or 1.7 mg/kg q8h iv | 3–7.5 mg/kg/d q8h iv |
Tobramycin | Aminoglycosides | G- organisms | Same as gentamicin iv | Same as gentamicin iv |
Amikacin | Aminoglycosides | G- organisms | 15 mg/kg qd or 7.5 mg/kg q12h iv | 10–15 mg/kg/d q12h iv |
Aztreonam | Monobactams | G- organisms; no staph or strep coverage | 1-2 g q6-12h iv | 100-150 mg/kg/d q6-8h iv |
imipenem | Carbapenems | Full broad spectrum G- and G+ coverage; also effective against anaerobs | 0.5-1.0 g q6h iv | 4 wk to 3 m/o: 100 mg/kg/d q6h > 3 m/o: 60-100 mg/kg/d q6h iv |
meropenem | Carbapenems | Full broad spectrum G- and G+ coverage; also effective against anaerobs | 1 g q8h iv | 60-120 mg/kg/d q8h iv |
ertapenem | Carbapenems | Full broad spectrum G- and G+ coverage; also effective against anaerobs; not covers pseudomonas | 1 gq24h iv | N/A iv |
Metronidazole | Others | Choice for anearobs | 30 mg/kg/d q6h iv | 30 mg/kg/d q6h iv |